Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 22:55 | 2026-05-18 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | SELL | $58.91 | 75,000 | $4,418,010 | 1,123,095 |
| 2026-05-20 22:08 | 2026-05-18 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.45 | 171,049 | $76,356 | 955,447 |
| 2026-05-20 21:41 | 2026-05-19 | BHC | Bausch Health Companies Inc. | Lee Frank D. | Director | SELL | $5.43 | 24,456 | $132,796 | 49,339 |
| 2026-05-20 21:33 | 2026-05-18 | PHVS | Pharvaris N.V. | Modig Berndt | Director, Officer | SELL | $29.22 | 2,292 | $66,977 | 137,500 |
| 2026-05-20 20:34 | 2026-05-19 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $567.94 | 9,500 | $5,395,399 | 40,513 |
| 2026-05-20 20:15 | 2025-05-18 | AVIR | Atea Pharmaceuticals, Inc. | Murphy Polly A. | Director | BUY | $4.17 | 6,100 | $25,446 | 92,145 |
| 2026-05-20 20:18 | 2026-05-18 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $39.79 | 5,000 | $198,972 | 25,000 |
| 2026-05-20 20:00 | 2026-05-19 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $75.69 | 3,500 | $264,915 | 153,902 |
| 2026-05-20 20:01 | 2026-05-18 | GYRE | GYRE THERAPEUTICS, INC. | Ye Weiguo | Officer | OPT+S | $6.38 | 9,320 | $59,419 | 700,000 |
| 2026-05-20 13:03 | 2026-05-18 | CNSP | CNS Pharmaceuticals, Inc. | Charles Faith L. | Director | BUY | $4.79 | 7,100 | $34,002 | 7,100 |
| 2026-05-19 20:05 | 2026-05-15 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bunnage Mark E. | Officer | SELL | $453.45 | 33 | $14,964 | 7,284 |
| 2026-05-19 20:04 | 2026-05-15 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $453.45 | 1,354 | $613,971 | 24,734 |
| 2026-05-19 20:30 | 2026-05-18 | BBIO | BridgeBio Pharma, Inc. | Trimarchi Thomas | Officer | SELL | $65.08 | 13,651 | $888,419 | 359,194 |
| 2026-05-19 20:05 | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Director | OPT+S | $7.53 | 259 | $1,950 | 12,040 |
| 2026-05-19 20:05 | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | Officer | OPT+S | $7.53 | 59 | $444 | 8,562 |
| 2026-05-19 20:05 | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | Officer | OPT+S | $7.53 | 77 | $580 | 7,838 |
| 2026-05-19 20:10 | 2026-05-15 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $18.76 | 3,000 | $56,280 | 3,622 |
| 2026-05-19 20:05 | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | DesRosier Thomas | Officer | OPT+S | $7.53 | 79 | $595 | 7,954 |
| 2026-05-19 20:05 | 2026-05-15 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Director | SELL | $43.49 | 3,250 | $141,343 | 52,250 |
| 2026-05-19 20:04 | 2026-05-18 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $26.76 | 1,032 | $27,616 | 143,934 |
| 2026-05-19 20:05 | 2026-05-18 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $26.76 | 1,108 | $29,650 | 227,367 |
| 2026-05-19 20:03 | 2026-05-18 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $26.76 | 1,129 | $30,212 | 467,665 |
| 2026-05-19 20:25 | 2026-05-15 | BBIO | BridgeBio Pharma, Inc. | Scott Randal W. | Director | OPT+S | $67.15 | 10,000 | $671,456 | 11,589 |
| 2026-05-19 20:03 | 2026-05-15 | ARDX | ARDELYX, INC. | RAAB MICHAEL | Director, Officer | OPT+S | $6.28 | 41,666 | $261,612 | 1,774,781 |
| 2026-05-19 21:35 | 2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer | BUY | $2.97 | 1,984 | $5,892 | 8,466 |
| 2026-05-19 20:15 | 2026-05-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Director | BUY | $10.58 | 1,000 | $10,580 | 9,450 |
| 2026-05-19 21:20 | 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $72.18 | 2,812 | $202,958 | 105,212 |
| 2026-05-19 23:15 | 2026-05-18 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $27.55 | 417 | $11,488 | 63,443 |
| 2026-05-19 22:42 | 2026-05-15 | PHVS | Pharvaris N.V. | Souverijns Wim | Officer | SELL | $29.92 | 10,000 | $299,163 | 45,111 |
| 2026-05-19 22:44 | 2026-05-15 | PHVS | Pharvaris N.V. | Abele Stefan Andreas | Officer | SELL | $29.82 | 8,748 | $260,864 | 35,194 |
| 2026-05-19 22:48 | 2026-05-15 | PHVS | Pharvaris N.V. | Glassman Robert | Director | OPT+S | $29.82 | 10,000 | $298,245 | 10,500 |
| 2026-05-19 22:04 | 2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer | BUY | $2.97 | 1,545 | $4,589 | 15,345 |
| 2026-05-19 22:06 | 2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.97 | 1,843 | $5,474 | 7,841 |
| 2026-05-19 22:02 | 2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer | BUY | $2.97 | 1,369 | $4,066 | 7,594 |
| 2026-05-19 21:37 | 2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer | BUY | $2.97 | 1,583 | $4,702 | 8,011 |
| 2026-05-19 21:17 | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Officer | BUY | $2.71 | 1,971 | $5,341 | 7,481 |
| 2026-05-19 20:38 | 2026-05-15 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer | BUY | $20.09 | 4,971 | $99,843 | 171,971 |
| 2026-05-19 20:39 | 2026-05-15 | ELAN | Elanco Animal Health Inc | Modi Rajeev A. | Officer | BUY | $20.35 | 4,911 | $99,939 | 160,812 |
| 2026-05-19 20:31 | 2026-05-18 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $567.04 | 9,500 | $5,386,856 | 40,513 |
| 2026-05-19 20:32 | 2026-05-18 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $567.31 | 10,000 | $5,673,098 | 18,876 |
| 2026-05-19 20:15 | 2026-05-15 | RYTM | RHYTHM PHARMACEUTICALS, INC. | German Christopher Paul | Officer | OPT+S | $92.21 | 4,643 | $428,131 | 0 |
| 2026-05-19 20:18 | 2026-05-15 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $19.87 | 100,000 | $1,986,880 | 1,122,626 |
| 2026-05-19 11:56 | 2026-05-15 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | BUY | $20.70 | 5,000 | $103,500 | 43,415 |
| 2026-05-19 11:00 | 2026-05-18 | HROW | HARROW, INC. | SILVERNAIL LAUREN P | Director | BUY | $31.00 | 1,000 | $31,000 | 1,000 |
| 2026-05-19 11:00 | 2026-05-18 | HROW | HARROW, INC. | Graves Adrienne L | Director | BUY | $31.07 | 1,000 | $31,070 | 1,000 |
| 2026-05-18 20:24 | 2026-05-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $20.29 | 12,500 | $253,649 | 191,641 |
| 2026-05-18 20:05 | 2026-05-14 | NBP | NovaBridge Biosciences | Cao Sean Wuxiong | Director, Officer | SELL | $1.99 | 21,399 | $42,584 | 35,073 |
| 2026-05-18 20:25 | 2026-05-15 | ACIU | AC Immune SA | Pfeifer Andrea | Director, Officer | SELL | $2.79 | 10,000 | $27,935 | 3,820,288 |
| 2026-05-18 20:15 | 2026-05-15 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Freund John Gordon | Director | OPT+S | $34.54 | 4,127 | $142,547 | 83,972 |
| 2026-05-19 01:27 | 2026-05-18 | MPLT | MapLight Therapeutics, Inc. | Kroeger Christopher A. | Director, Officer | SELL | $27.19 | 118,235 | $3,214,999 | 1,394,094 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.